Interviews

It is imperative individuals with cardiovascular diseases remain active despite COVID-19 lockdowns, said Antonio Pelliccia, MD, senior consultant and chief of cardiology at the Institute of Sports Medicine and Science, of the Italian National Olympic Committee.

Melissa L. Johnson, MD, associate director for lung cancer research at Sarah Cannon Research Institute and partner in Tennessee Oncology, discussed the biggest gains in the lung cancer space that have contributed to improved survival for patients.

It's a great time to be a doctor treating patients with heart failure, given the development of 2 fantastic new treatments within the space of 5 years, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.

The new guidelines can help cardiologists better advise patients with CVD on physical activity, said Antonio Pelliccia, MD, senior consultant and chief of cardiology at the Institute of Sports Medicine and Science, of the Italian National Olympic Committee.

It's interesting that we saw such a clear U-shaped mortality curve for serum bicarbonate levels in a patient population where we usually don't think about measuring bicarbonate, said Manan Pareek, MD, PhD, FAHA, FESC, an internal medicine hospital resident at the Yale University School of Medicine.

Having 2 trials that both show benefits of SGLT2 inhibitors in heart failure hospitalizations can only encourage the use of these drugs, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.

Advances in imaging have made assessment of atherosclerosis non-invasive, while the EVAPORATE trial demonstrates how cardiac CT can assist in looking at a host of different therapies, said Matthew Budoff, MD, professor of medicine at the David Geffen School of Medicine at UCLA and investigator at The Lundquist Institute.

There is a certain element of antiscience sentiment in the United States and Europe that Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, finds troubling.

It's very important to take the EMPEROR-Reduced and DAPA-HF trials together as being complementary, said Milton Packer, MD, of Baylor University Medical Center in Dallas and University of Texas Southwestern Medical School.

Early rhythm control was associated with a marked reduction in cardiovascular deaths among at-risk stroke patients, said Paulus Kirchhof, MD, director of the department of cardiology at the University Heart and Vascular Center UKE Hamburg, and professor of cardiovascular medicine at the Institute of Cardiovascular Sciences at the University of Birmingham.

When results from the EMPA-REG OUTCOME trial came out, nobody was expecting empagliflozin to have a particularly robust benefit on heart failure and several questions were raised as a result, said Javed Butler, MD, MPH, MBA, chairman for the Department of Medicine at the University of Mississippi.

Through EVAPORATE, we've been able to show at 18 months that patients taking icosapent ethyl (Vascepa) have less plaque and that there is some atherosclerosis regression, marking mechanisms of benefit for these patients, said Matthew Budoff, MD, professor of medicine at the David Geffen School of Medicine at UCLA and investigator at The Lundquist Institute.

Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, spoke recently with The American Journal of Managed Care®. During the interview, we asked about health burdens that disproportionately affect Black and other multiracial US communities.

By increasing access and awareness of mental health services, employers can assist in addressing concerns precipitated by pandemic and racial injustice to curb potentially severe and persistent mental illness, said Joe Grasso, PhD, clinical director of partnerships at Lyra Health.

The impact of impaired sleep, which is more frequent among adolescents, was associated with a greater risk of asthma and allergies among this age group, but association does not equal causation. As a result, these associations warrant greater investigation, as well as the potential effects of social determinants of health such as race and socioeconomic status, said Lakiea Wright, MD, practicing physician at Brigham and Women's Hospital in Boston and the medical director at Thermo Fisher Scientific.

Whether you fit into the older or younger demographic, staying up to date on eye care is key as growing risks of cataracts, glaucoma, diabetic retinopathy, and macular degeneration are leading causes of blindness. Moreover, reducing the structural barriers to eye care, which disproportionately affect blacks and Afro Latinos, can assist in advancing the availability of eye health nationwide, said Daniel Laroche, MD, director of Glaucoma Services and president of Advanced Eye Care of New York.

The COVID-19 pandemic spotlighted the lack of preparation and notable disruptions in the US health care delivery system. To optimally transition to delivering high quality and affordable care, findings from a report by the National Alliance of Healthcare Purchaser Coalitions and the Council for Accountable Physician Practices (CAPP) suggest that enhanced care coordination, greater investment in delivery systems and primary care, and aligning reimbursement with patient outcomes is warranted, said Norman Chenven, MD, vice chairman of CAPP.

All patients with cancer deserve a fair shot at survival, and this includes access to clinical trials. At present, however, access to these trials is restricted under Medicaid coverage, necessitating a need for change at the federal policy level, noted Fumiko Chino, MD, assistant attending radiation oncologist at Memorial Sloan Kettering Cancer Center in New York, in an interview for ASCO20 Virtual, this year’s annual meeting of the American Society of Clinical Oncology.

In addressing the COVID-19 pandemic, a more active-based approach is warranted among employers to optimize care. Through detailed databases and a greater focus on population health, Paladina Health has promoted this transition to a more informed, value-based health care delivery system, said Kirk Rosin, chief revenue officer of Paladina Health.

The effect of chronic fibrosing ILD with progressive phenotype on personal relationships with friends and family.

Today, The American Journal of Managed Care® is speaking with 2 experts to discuss the root causes of racial inequities in cancer care. Dr John Carpten, professor at the University of Southern California Keck School of Medicine, outlines what needs to happen to improve cancer outcomes for minority populations and support minority scientists, and Dr Russell Ledet, president of The 15 White Coats and medical student at Tulane University School of Medicine, explains the steps to breaking down the barriers to medical school for those from marginalized communities.

Concerns and precautions for a patient living with chronic fibrosing ILD with progressive phenotype during the coronavirus pandemic.

Based on findings from our COVID-19 Reopening the Workplace Survey, employers are increasing focus on safety, enhancing well-being programs, and providing flexibility to accommodate employees who may be at-risk or may shoulder a greater caregiving responsibility, said Regina Ihrke, senior director and wellbeing leader of Willis Towers Watson in North America.

Insurance coverage concerns and difficulties while seeking care for chronic fibrosing ILD with progressive phenotype.

The Affordable Care Act encourages preventive care, like cancer screenings, by eliminating copays, so that additional years will only see the number of lives saved grow, noted Fumiko Chino, MD, assistant attending radiation oncologist at Memorial Sloan Kettering Cancer Center in New York, in an interview prior to ASCO20 Virtual, this year’s annual meeting of the American Society of Clinical Oncology.

The management of chronic fibrosing ILD with progressive phenotype through immunosuppressants and oxygen is examined as well as the effect on lifestyle.

A patient perspective of initial diagnosis of chronic fibrosing ILD with progressive phenotype and the subsequent impact on quality of life.

Dawn Repola recalls her journey to diagnosis of chronic fibrosing interstitial lung disease with progressive phenotype and relays frustrations along the way.